Shanghai Junshi Bioscience Co., Ltd.
Clinical trials sponsored by Shanghai Junshi Bioscience Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for lung cancer patients when targeted drugs stop working Results expected Sep 2026 (estimated)
- New drug combo targets Hard-to-Treat cancers Results expected Dec 2026 (estimated)
- New hope for tough lymphoma: experimental drug JS203 enters human testing Results expected Dec 2026 (estimated)
- Can an immunotherapy drug keep liver cancer at bay after surgery? Results expected Dec 2026 (estimated)
- Promising immunotherapy combo takes on advanced liver cancer Results expected Dec 2026 (estimated)
-
New antibody pair takes aim at advanced liver cancer in major trial
Disease control Not yet recruitingResearchers are testing whether a new combination of two antibodies, JS207 and JS007, works better than the standard first-line treatment of toripalimab plus bevacizumab for advanced liver cancer. The trial enrolls about 560 adults with liver cancer that cannot be removed by surg…
Phase 3 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New antibody JS203 takes on rituximab in Head-to-Head lymphoma trial
Disease control Not yet recruitingResearchers are testing whether an experimental antibody called JS203, added to gemcitabine and oxaliplatin chemotherapy, helps adults with diffuse large B-cell lymphoma (DLBCL) that has come back or stopped responding to treatment. The trial compares this combination against the…
Phase 3 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC